With their applications in cancer, autoimmunity, and rare diseases, cellular therapies have revolutionized medicine. Unlike traditional medications, these products incorporate live cells that respond to external factors and can vary between production batches. The complexity of the process calls for more rigorous quality control and puts lot release testing of cellular therapy at the focus of commercial success.
Each production lot must demonstrate compliance with certain requirements for quality, safety, identity, purity, and efficacy before being delivered to patients. A failure in such a test may cause many problems, including treatment delays and additional expenses. For any company planning to move from clinical development to commercial production, an efficient lot release approach is imperative.
What Is Lot Release Testing in Cell Therapy?
Release testing is the final quality control step performed prior to the release of a manufactured cell therapy product. Unlike chemical-based biologics, where the degree of compositional consistency can be quantified using standard assays, cellular products require multiple forms of analysis.
The components of a comprehensive release test usually include:
- Cell identity
- Cell viability
- Purity
- Potency
- Sterility
- Endotoxin content
- Mycoplasma contamination
- Genetic stability (if necessary)
- Specific CQAs of the product
Regulatory agencies expect acceptance criteria to be developed based on science for each release criterion. Such criteria must be consistent during both process development and commercial manufacture.
Why Commercialization Depends on Reliable Release Testing
However, commercial-scale manufacturing brings in variables which may not be apparent in early clinical development processes. Variations in raw materials, donor variation, equipment, and production scales can also have an impact on the end product.
There are several key objectives of lot release testing:
Patient Safety
Cell therapy is administered to patients; often, it involves administering therapy to people who may suffer from severe life-threatening diseases or have an impaired immune system. Lot release testing helps ensure that every lot is devoid of any microbes but remains viable and biologically functional.
Regulatory Compliance
FDA, EMA, or other international regulatory authorities will need documented proof that every lot of product made complies with predetermined quality criteria. Well-planned testing helps with regulatory compliance needs and marketing authorization.
Manufacturing Reproducibility
Reproducibility is key for commercial success. One will need to prove that every manufactured batch behaves in the same way irrespective of the date of manufacturing, personnel, or site of production.
Supply Chain Dependability
Most autologous therapies have a very limited time window for manufacturing. Any delays resulting from incomplete or delayed testing will push back the timeline of treatment.
The Growing Importance of Potency Assays
Of all release tests, the potency test is considered one of the hardest.
The potency assay is one that measures the biological activity causing the therapeutic response as opposed to the mere detection of cellular content.
These include:
- Tumor cell killing assays for CAR-T cells
- Cytokine secretion analysis
- Immune activation assays
- Cytotoxicity assays
- Cell proliferation assays
- Differentiation assays
Validation of these assays becomes difficult due to biological variations.
The trend among regulatory authorities is towards correlating potency assays with the product’s mechanism of action rather than surrogate markers.
The Role of Immunoassay Testing in Release Testing
Immunoassay test services have today become essential across the cell therapy manufacturing process as well as quality control operations.
Immunoassays enable very precise determination of proteins, cytokines, growth factors, antibodies, and biomarkers that determine the quality of a product.
Some of the common uses are as follows:
- Cytokine quantification using ELISA
- Determination of residual proteins
- Antigen identification
- Validation of biomarkers
- Support for potency assays
- Process monitoring
Due to the high sensitivity and reproducibility provided by immunoassays, these are often used in conjunction with flow cytometry, PCR, and cell-based functional assays as part of a release testing process.
Why Cell Therapy Process Development Cannot Ignore Release Testing
One of the major pitfalls developers make when designing advanced therapies is treating release testing as an endpoint activity.
Cell therapy process development should include analytical testing from early on.
There are several benefits to early integration:
Process Understanding
The data collected help explain how process parameters influence critical quality attributes.
Facilitated Scale-Up
Analytical methods developed during process development easily translate to commercial manufacture.
Decreased Regulatory Risk
Early analytical characterization enhances CMC documentation prepared for regulatory submissions.
Cost Savings
Early process characterization helps avoid costly manufacturing issues later in the process.
The modern approach to process development integrates the process development with analytical method development rather than separating them.
Advanced Analytical Technologies Supporting Lot Release
Today’s release testing relies on multiple analytical platforms working together.
Common technologies include:
| Technology | Primary Purpose |
| Flow Cytometry (FACS) | Cell identity, phenotype, viability |
| PCR / qPCR | Genetic identity, vector analysis, mycoplasma detection |
| ELISA Immunoassays | Protein quantification, cytokines, potency |
| Sterility Testing | Microbial contamination |
| Endotoxin Testing | Pyrogen detection |
| Cell-Based Functional Assays | Biological potency |
| Automated Cell Counting | Viability and concentration |
| Stability Testing | Shelf-life verification |
Each analytical method contributes to a complete understanding of product quality rather than relying on a single measurement.
Challenges Facing Commercial Cell Therapy Manufacturers
Even with the tremendous advancement in technology, lot release testing still faces some challenges.
Shelf Life of the Product
The fresh cellular therapy product can take hours to days to be released after manufacturing. The test laboratories thus need to provide timely analysis without compromising the quality of the results.
Variability of Biological Products
Biological products derived from donors inherently have variability compared to normal biological products.
Standardization of Assays
Most of the assays used to measure potency are specific to a given product. It makes standardization very hard.
Regulatory Expectations Globally
Companies that manufacture internationally need to meet the requirements of various regulations even as they conduct testing.
Technology Transfer
Validation of methods in development laboratories, CDMOs, and commercial manufacturing requires extensive qualification.
Building an Efficient Commercial Release Strategy
Commercialization success requires integrating manufacturing, analysis, and quality into an end-to-end process.
Best practices:
- Determine critical quality attributes early on.
- Create stability-indicating analysis methods.
- Validate assays prior to pivotal clinical trials.
- Automate data management wherever feasible.
- Carry out analysis comparability studies following process modifications.
- Utilize GMP facilities that have experience working with advanced therapies.
- Implement rapid release testing for short-lived cellular therapies.
Organizations that invest early in analytical infrastructure typically reduce commercial manufacturing delays while strengthening regulatory readiness.
The Value of Integrated Testing Services
Today, many manufacturers choose to collaborate with CDMOs that offer integrated analytical services throughout the entire product development process.
The right collaboration will allow one to use the following services at once:
Process Development
- Analytical Method Development
- Immunoassays
- GMP Manufacturing
- Bioanalysis
- Quality Control
- Lot Release Testing for Cell Therapy
- Regulatory Documentation
Such integration provides better communication between manufacturing and quality control departments and minimizes risks during technology transfer. It will also help to accelerate the process of commercialization. Providers with their own GMP manufacturing and quality control laboratories will be able to help with such processes.
Conclusion
Cell therapy manufacturing for commercial purposes requires much more than just efficient production processes. Each batch needs to provide consistent safety, identity, purity, and potency, and be compliant with regulations, before being delivered to the patients. As cell therapies become more individualized and manufacturing processes scale up, lot release testing strategies will remain essential for commercial success.
No less important is the integration of analytical development processes with cell therapy manufacturing processes, making sure that all quality attributes are built into the manufacturing process and not assessed at the very end. With advanced immunoassay testing services, comprehensive lot release testing allows manufacturers to minimize risks and satisfy all regulatory requirements.
Strengthen your cell therapy commercialization strategy with trusted analytical expertise from Xellera Therapeutics.
